Scholarlink

Background <p>Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are characterized by persistent airway inflammation and airflow limitation. Measuring airway inflammation may be of value both in research and clinical practice. Calprotectin, a protein associated with neutrophil activation, serves as a potential biomarker for airway inflammation. This study evaluates the performance of a particle enhanced turbidimetric immunoassay (PETIA) for measuring calprotectin in sputum samples.</p> Methods <p>Thirty sputum samples from unique patients were collected at the Department of Clinical Microbiology in Lund, Sweden and treated with dithiothreitol (DTT) before analysis. Calprotectin levels were measured using a PETIA on an automated turbidimetric analysis system (Atellica CH 930 Analyzer). The 30 samples were analyzed in triplicate the day of sample collection (Day 0), after storage at 4&#xa0;°C for two to four days (Day 2–4), and after six to seven days (Day 6–7). An additional aliquot from each sample was stored at -20&#xa0;°C and analyzed after 41 to 58 days (Day 41–58). Precision, accuracy, and stability of the assay were assessed. Precision was evaluated using pooled- and individual sputum samples while accuracy was determined through spiking studies and dilution linearity. Stability was tested by comparing calprotectin levels Day 2–4, Day 6–7 and Day 41–58 with Day 0, respectively. Instability equations were calculated for samples stored at 4&#xa0;°C and at -20&#xa0;°C, respectively.</p> Results <p>Three different pools were each analyzed 25 times during five days. The coefficient of variation (CV) for the calprotectin concentration was below 3% for all three. Considering precision based on individual samples, 90% of 120 triplicates had a CV below 7%. These figures indicate an acceptable precision. The spiking and dilution studies showed that measured calprotectin concentrations matched expected levels, with deviations below 10%. Calprotectin concentrations Day 2–4, Day 6–7 and Day 41–58 did not significantly differ from Day 0, and the slope of the instability equations did not significantly differ from 0. It implies that calprotectin concentration can be measured in DTT treated sputum stored for up to one week at 4&#xa0;°C and up to two months at -20&#xa0;°C.</p> Conclusion <p>The evaluated PETIA, running on an automated system, provides a promising method for measuring calprotectin in sputum, supporting its potential use in both clinical and research applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of a Particle Enhanced Turbidimetric Immunoassay (PETIA) for detecting calprotectin in sputum samples

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月21日

查看全文
  • Magnus Förnvik Jonsson,
  • Ulrik Hägglund,
  • My Eltén ,
  • Torgny Sunnerhagen ,
  • Muna Al-Jammal ,
  • Magnus Paulsson

摘要

Background

Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are characterized by persistent airway inflammation and airflow limitation. Measuring airway inflammation may be of value both in research and clinical practice. Calprotectin, a protein associated with neutrophil activation, serves as a potential biomarker for airway inflammation. This study evaluates the performance of a particle enhanced turbidimetric immunoassay (PETIA) for measuring calprotectin in sputum samples.

Methods

Thirty sputum samples from unique patients were collected at the Department of Clinical Microbiology in Lund, Sweden and treated with dithiothreitol (DTT) before analysis. Calprotectin levels were measured using a PETIA on an automated turbidimetric analysis system (Atellica CH 930 Analyzer). The 30 samples were analyzed in triplicate the day of sample collection (Day 0), after storage at 4 °C for two to four days (Day 2–4), and after six to seven days (Day 6–7). An additional aliquot from each sample was stored at -20 °C and analyzed after 41 to 58 days (Day 41–58). Precision, accuracy, and stability of the assay were assessed. Precision was evaluated using pooled- and individual sputum samples while accuracy was determined through spiking studies and dilution linearity. Stability was tested by comparing calprotectin levels Day 2–4, Day 6–7 and Day 41–58 with Day 0, respectively. Instability equations were calculated for samples stored at 4 °C and at -20 °C, respectively.

Results

Three different pools were each analyzed 25 times during five days. The coefficient of variation (CV) for the calprotectin concentration was below 3% for all three. Considering precision based on individual samples, 90% of 120 triplicates had a CV below 7%. These figures indicate an acceptable precision. The spiking and dilution studies showed that measured calprotectin concentrations matched expected levels, with deviations below 10%. Calprotectin concentrations Day 2–4, Day 6–7 and Day 41–58 did not significantly differ from Day 0, and the slope of the instability equations did not significantly differ from 0. It implies that calprotectin concentration can be measured in DTT treated sputum stored for up to one week at 4 °C and up to two months at -20 °C.

Conclusion

The evaluated PETIA, running on an automated system, provides a promising method for measuring calprotectin in sputum, supporting its potential use in both clinical and research applications.